SYRMA Q4 FY26 Concall Summary & Key Takeaways (SYRMA)

SYRMA Q4 FY26 (Mar-2026 Qtr) Earnings call highlights: Key takeaways, performance, financial metrics, outlook and guidance, concerns and management tone.

Syrma SGS Technology Ltd (SYRMA) Q4FY26 Concall Summary - Mar-2026 Qtr

Performance Overview

  • The company reported a landmark quarter and fiscal year, characterized by strong execution, significant margin expansion, and a strengthened balance sheet, transitioning from a net debt position to a net cash position.
  • All key business drivers, including Automotive, Industrial, Healthcare, Exports, and ODM, performed exceptionally well, with revenue excluding the consumer business growing by a healthy 38%.
  • The company successfully exceeded its initial guidance on all major parameters for the year, including EBITDA, revenue growth, and export targets, while also improving the working capital cycle.
  • A robust order book of INR 6,600 crores as of March-end provides strong visibility for future growth, with a diversified mix across key verticals like Automotive, Consumer, and Industrial.
  • The management expressed strong confidence for FY27, backed by a solid Q4 revenue run rate, a healthy order pipeline, and strategic investments that position the company for sustained growth.

Financial Metrics

Log in to Stocksigma to read the Financial Metrics section of this summary.

Operating Performance / Business Segments

Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.

Key Discussions & Insights

Log in to Stocksigma to read the Key Discussions & Insights section of this summary.

Outlook and Guidance

Log in to Stocksigma to read the Outlook and Guidance section of this summary.

Challenges / Concerns

Log in to Stocksigma to read the Challenges / Concerns section of this summary.

Industry / Competitive Landscape

Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.

Overall Summary

Log in to Stocksigma to read the Overall Summary section of this summary.